Items Tagged ‘CheckMate 040 nivolumab’

May 18th, 2017

Opdivo Precision Cancer Medicine Improves Outcomes in Advanced Liver Cancer

By

Results from the CheckMate 040 clinical trial have been recently reported and found that Opdivo (nivolumab), an immuno-oncology drug which acts by modulating the immune system, produces durable responses with long-term survival rates in patients with liver cancer, regardless of whether or not patients were infected with Hepatitis B or C.  These study results were […]

View full entry

Tags: CheckMate 040 nivolumab, immuno-oncology, Liver Cancer, News, opdivo, PD-1, Precision Cancer Medicine